SUMMARY The most readily available source of monoamine oxidase in man is the platelet, although only the B form of the enzyme is represented in this site. Platelet activity is higher in women than in men. The enzyme activity is generally stable and is partly under genetic control. There is some evidence that individuals with low activity have a higher psychiatric morbidity than those with high activity.
The insoluble mitochondrial enzyme, monoamine oxidase (MAO) (EC. 1.4.3.4) , is the subject of a voluminous literature (for review, see refs 1-3) . Most of the biologically active monoamines it numbers among its substrates are either known neurotransmitters or neurotransmitter candidates. Thus, even though MAO is widely distributed through the body, it is not surprising that its possible role in neuropsychiatric disorders has figured most prominently in these research publications.
One of the major constraints to its direct study in man is the problem of accessibility. Although occasional attempts have been made to quantify enzyme activity in biopsy samples from a variety of different sources, including jejunal mucosa,45 skin fibroblasts,6 buccal scrapings,7 and muscle,8 for most practical purposes the only readily accessible source of the enzyme for routine studies derives from certain formed elements of the blood. Although lymphocytes, which may be difficult to harvest, have on occasion been used as enzyme source,9 the blood platelet, which is relatively easy to obtain in pure *Present address: Department of Psychiatry, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF. preparation, has been the tissue of choice to an overwhelming extent.
Not that the human platelet enzyme is ideal to provide an insight into the status of central nervous system MAO. A widely accepted working classification of the enzyme into A and B forms exists, based on the differential inhibitory ability of the drug clorgyline;10 type A is defined as the form sensitive to clorgyline, and this oxidatively deaminates noradrenaline and 5-hydroxytryptamine but not phenylethylamine; type B is preferentially inhibited by deprenyl"l and selectively deaminates phenylethylaminel2 and tele-methylhistaminel3 rather than noradrenaline and 5-hydroxytryptamine. Tyramine and dopamine are substrates for both forms. It is quite clear that the human platelet is a pure source of MAO B,14 as, for that matter, is human lymphocyte.9 Although the human brain has a relatively high MAO B content15 and dopamine is predominantly metabolised by MAO B in striatum and accumbens, 16 substantial MAO A activity is also present. Even so, and as we discuss below, changes in platelet activity have In a large new study of over 120 headache patients41 we have found a significant decrease in activity in men with classical migraine, tension headache, and cluster headache, but no significant change in men with common migraine or in females with any manifestation of the disease compared with control. In this study4' we also showed that MAO activity is relatively stable with repeated assays on the same individual, some over four-year intervals. This was particularly striking in certain subjects with permanently low activity. There was no difference in mean activity of patients taking drugs commonly used in migraine treatment, aspirin, ergotamine, diazepam or clonidine, compared with untreated patients.39
Three studies have compared platelet activity in patients with a history of dietary migraine and in those without;37 39 41 the mean was similar in each. Thus, although more migrainous patients do seem to have lower platelet MAO activity than controls, it is unlikely that any genetic enzymatic deficit can account for most reports of dietary migraine.
Several independent studies have also found significant transitory decreases in platelet MAO activity during a single migraine attack.36 39 138 However, the transitory reduction in platelet activity may well be a localised platelet effect, deriving perhaps from some circulating non-specific plateletdamaging agent. Platelets from migrainous patients aggregate more readily in vitro than control preparations, even outside an attack.139 140 
